Bionano Genomics — Q3 2026 Earnings Summary

Bionano Genomics reported third-quarter 2026 total revenue of $8.3 million, a 12% increase from the prior year period, driven by a 24% rise in consumables revenue to $4.7 million. The company sold 9,870 flowcells during the quarter, representing an 18% year-over-year increase, while achieving a gross margin of 48%. Operating expenses decreased by 12% to $10.5 million, and the company reiterated its full-year 2026 revenue guidance range of $31 million to $33 million.